Hansa Biopharma — Februar 2022
-
Hansa Biopharma year-end report 2021
-
Investor Road Show Presentation Q4 2021:
-
Hansa Biopharma Conference Call - Fourth Quarter 2021 Business Update:
-
"Hansa Biopharma to host conference call to provide Year-End report for 2021 and Business Update"
"The event will be hosted by Hansa Biopharma’s CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English."
The webcast will be available on:
-
Fra Redeye's konklusion d.d.:
"On all accounts, Hansa can already point to significant progress. Hansa is also expanding the number of partners and collaborations, and Imlifidase is in the process of enhancing its potential as a platform candidate in different indications."
-
"All this positive progress is balanced by limited prospects of near term substantial recurring sales progress. This is, however, also reflected in a very modest valuation. Our base case is SEK 410, and Hansa is currently trading well below our Bear case of SEK 175."
-
-
Helt enig exitnu. Lige nu skriver du alene- håber du holder ved. Hansa er et rent bargain lige nu. Ingen tvivl om at der er et meget stort upside herfra
-
Fuldstændigt sindsygt igen, shorterbanden anført af MSE nettosælger ca. 400.000 aktier i dag, på nyheder markedet allerede kendte, eneste negative er forsinkelse af GBS studie grundet covid 19.
-
Enig Optimus - Siden kapitaludvidelsen til kurs 250 er den eneste negative nyhed patientoptaget på AMR og GBS er forsinket lidt (grundet corona). Derudover er der kommet ny indikation i Bonemarrow, Genterapi deal med AskBio og samarbejde med Argenx. Alt kører på skinner, men udrulningen tager tid som også meldt ud.
-
Ja kapitaludvidelsen hænger som en mørk sky over Hansa lige nu, en mulighed er vel at lave lånefinansiering ala Zealand style for finansiering til start 2024, her kommer US studie-resultater og ville formentlig være perfekt for optagelse på Us-børs.
-
H1 2024 U.S. BLA submission.
-
Hansa Biopharma AB (publ) (HNSBF) CEO Søren Tulstrup on Q4 2021 Results - Earnings Call Transcript - February 3, 2022:
-
Søren Tulstrup - President & CEO
Donato Spota - CFO
Klaus Sindahl - IR
Conference Call Participants
Christopher Uhde - SEB
Adam Karlsson - ABG Sundal Collier
Johan Unnerus - Redeye
Zoe Karamanoli - RBC Capital Markets
Dominic Rose - Intron Health
Douglas Tsao - H.C. Wainwright
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind